S Kant Healthcare

Product category
  • Sulfadoxine-pyrimethamine + amodiaquine in child-friendly dispersible formulation

  • Chemoprevention

Therapeutic indication
  • Seasonal Malaria Chemoprevention for children 3 to 59 months in eligible region
  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months 

  • 75% reduction in malaria episodes in pivotal trials

Key features
  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission

  • Average cost to protect a child: US$3.40 per year (drug costs + delivery)

  • Dossier submitted for Prequalification and ERP approval

Next milestone
  • First distributions in countries expected in 2019
MMV Project Director
  • Dr AndrĂ©-Marie Tchouatieu